| 摘要 |
1,201,953. 3-Amino-rifamycins S and SV. CIBA Ltd. 24 Oct., 1967 [25 Oct., 1966], No. 48303/67. Heading C2A. Novel 3-amino-rifamycin S and 3-amino rifamycin SV derivatives of formulµ respectively, and of their hydrogenated derivatives at least partially hydrogenated in positions 16, 17, 18, 19, 28 and 29, in which R represents the residue of a carbocyclic aromatic or heterocyclic aromatic compound, any substituent of which in the ortho position to the carbon atom linked with the -NH group is different from a free primary amino group, free OH or free SH group, and salts thereof including quaternary ammonium salts, are prepared by reacting rifamycin S or rifamycin O or a hydrogenated derivative thereof, with a primary amine of formula NH 2 -R, in which R has the above meaning. If desired, the resultant compound (A) if a hydroquinone may be oxidized to a quinone (i.e. a 3-aminorifamycin S); (B) if a quinone may be reduced to a hydroquinone (i.e. a 3-amino rifamycin SV); (C) may be hydrogenated or (D) may be converted to a salt. Oxidization (A) may be by means of hydrogen peroxide, ammonium persulphate or potassium ferricyanide. Reduction (B) may be by means of hydrosulphite, dithionite or ascorbic acid (preferred) or a salt thereof. Hydrogenation (C) is with catalytically activated hydrogen. R of the above general formulae may be phenyl, naphthyl, pyridyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrazinyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl or triazolyl. Preferred compounds are 3-anilino rifamycins S and SV and 3-[(4- pyridyl)-amino]-rifamycin SV. Salts are formed with alkali metals and with many inorganic are organic acids (specified). The picrates may be used for purifying the bases by converting the bases into salts isolating the salts and liberating the bases therefrom. A pharmaceutical composition for oral, topical or parenteral administration to humans and animals comprises a 3-amino-rifamycin S or 3-amino-rifamycin SV of Formulµ I or II and a carrier e.g. animal fodder. |
